# BIOCRYST PHARMACEUTICALS, INC. (BCRX) · Edgar & Edgarette company card

> Biocryst Pharmaceuticals (BCRX) grew revenue 94.1% in FY2025 to $875 million, operating margin 39.0% against a -15.8% median for biological products, (no diagnostic substances), equity -23.2% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 882796 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/BCRX) · [JSON](https://www.pops4.com/boards/company/BCRX.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $875M |
| Revenue growth, 1 year | 94.1% |
| Revenue growth per year | 53.6% |
| Operating margin | 39.0% (prior year -0.6%) |
| Net margin | 30.2% |
| Operating cash flow | $347M |
| Capital spending | $2M |
| Free cash flow | $345M |
| Cash | $90M |
| Long-term debt | $0 |
| Total assets | $514M |
| Total equity | −$119M |
| Equity ÷ assets | -23.2% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -2.63 (distress zone)
- Piotroski F: 7 of 9 (solid)
- Beneish M: -2.19 (below the −1.78 line)
- Health Harbor boat: Old boat · three warning signs · filed restructuring or exit costs in the last 12 months; liabilities exceed assets (often from years of share buybacks, not always distress); revenue is hard to predict: its 80% range is ±27%
- Cash Compass: Cash cow later · growing fast, and already turning revenue into cash

## Edgarette's reading

Exposure: revenue $874.8M (FY2025), total debt $0K. Experience: revenue up 94.1% on the year, up 53.6% a year over 4 years; operating margin 39.0%, up from -0.6%. Soundness: equity -23.2% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $1.1B and $1.9B next year (method v4.1: its own 4-year record of growth weighed at 50% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $975.0M to $2.2B. A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin 39.0% against a -15.8% median; growth 94.1% against 21.4%.

Range logged 2026-10-30, receipt 6ec205230410f26a, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 2.05 Restructuring or exit costs: 1, latest 2026-06-29 ([filing](https://www.sec.gov/Archives/edgar/data/882796/000117184326004333/0001171843-26-004333-index.htm))
- Item 5.02 Director or officer change: 2, latest 2026-06-12 ([filing](https://www.sec.gov/Archives/edgar/data/882796/000117184326004096/0001171843-26-004096-index.htm))

## Recent filings

- 10-Q · filed 2026-08-05 · [filing](https://www.sec.gov/Archives/edgar/data/882796/000162828026053300/0001628280-26-053300-index.htm)
- 8-K · filed 2026-08-05 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/882796/000117184326005223/0001171843-26-005223-index.htm)
- 8-K · filed 2026-06-29 · 2.05 Costs Associated with Exit or Disposal Activities; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/882796/000117184326004333/0001171843-26-004333-index.htm)
- 8-K · filed 2026-06-12 · 5.02 Departure or Election of Directors; Appointment of Officers; 5.07 Submission of Matters to a Vote of Security Holders; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/882796/000117184326004096/0001171843-26-004096-index.htm)
- 10-Q · filed 2026-05-06 · [filing](https://www.sec.gov/Archives/edgar/data/882796/000162828026031238/0001628280-26-031238-index.htm)
- 8-K · filed 2026-05-06 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/882796/000117184326003052/0001171843-26-003052-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0000882796.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=882796

## Cite

POPS4, Edgar & Edgarette: BIOCRYST PHARMACEUTICALS, INC. (BCRX) company card, from the company's own SEC filings, accessed 2026-11-02, https://www.pops4.com/boards/company/BCRX. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.